Thomas Rudiger

Summary

Country: Germany

Publications

  1. ncbi Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry
    T Rudiger
    Department of Pathology, University of Wurzburg, Germany
    Am J Surg Pathol 22:1184-91. 1998
  2. ncbi Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma)
    T Rudiger
    University of Wurzburg, Germany
    Ann Oncol 9:S31-8. 1998
  3. ncbi [Peripheral NK/T-cell lymphoma]
    T Rudiger
    Institut fur Pathologie, Universitat Wurzburg
    Pathologe 28:55-8. 2007
  4. ncbi Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma
    T Rudiger
    Department of Pathology, University of Wurzburg, Germany
    Ann Oncol 13:44-51. 2002
  5. ncbi Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists
    Thomas Rudiger
    Institute of Pathology, Technical University Munchen, Germany
    Am J Surg Pathol 26:873-82. 2002
  6. ncbi [WHO-classification of malignant lymphomas]
    T Rudiger
    Institut fur Pathologie, Universitat Wurzburg
    Radiologe 42:936-42. 2002
  7. ncbi [Interlaboratory trial 2000 " Immunohistochemistry" of the German Society for Pathology and the Professional Association of German Pathologists]
    T Rudiger
    Institut fur Pathologie, Universitat Wurzburg
    Pathologe 24:70-8. 2003
  8. ncbi Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma
    Ludmila Boudova
    Department of Pathology, Josef Schneider Str 2, D 97080 Wurzburg, Germany
    Blood 102:3753-8. 2003
  9. ncbi Peripheral T-cell lymphoma with progression to a clonally related, Epstein Barr virus+, cytotoxic aggressive T-cell lymphoma: evidence for secondary EBV infection of an established malignant T-cell clone
    Rupert Langer
    Institute of Pathology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Am J Surg Pathol 34:1382-7. 2010
  10. ncbi CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies
    Eva Geissinger
    Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany
    Leuk Lymphoma 50:1010-6. 2009

Detail Information

Publications24

  1. ncbi Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry
    T Rudiger
    Department of Pathology, University of Wurzburg, Germany
    Am J Surg Pathol 22:1184-91. 1998
    ....
  2. ncbi Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma)
    T Rudiger
    University of Wurzburg, Germany
    Ann Oncol 9:S31-8. 1998
    ..A distinctive subset of cases representing mediastinal large B-cell lymphomas with features of Hodgkin's lymphoma was identified...
  3. ncbi [Peripheral NK/T-cell lymphoma]
    T Rudiger
    Institut fur Pathologie, Universitat Wurzburg
    Pathologe 28:55-8. 2007
    ..In addition, there is a clonal infection by Epstein-Barr virus in the T-lymphocytes. In the differential diagnosis, B-cell lymphomas are more frequent at all localizations than T- or NK-cell lymphomas...
  4. ncbi Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma
    T Rudiger
    Department of Pathology, University of Wurzburg, Germany
    Ann Oncol 13:44-51. 2002
  5. ncbi Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists
    Thomas Rudiger
    Institute of Pathology, Technical University Munchen, Germany
    Am J Surg Pathol 26:873-82. 2002
    ..Multisample tissue blocks provide a promising tool to standardize quantitative immunohistochemical parameters, such as receptor or proliferation scores...
  6. ncbi [WHO-classification of malignant lymphomas]
    T Rudiger
    Institut fur Pathologie, Universitat Wurzburg
    Radiologe 42:936-42. 2002
    ..Therefore,patients should be treated within such a study...
  7. ncbi [Interlaboratory trial 2000 " Immunohistochemistry" of the German Society for Pathology and the Professional Association of German Pathologists]
    T Rudiger
    Institut fur Pathologie, Universitat Wurzburg
    Pathologe 24:70-8. 2003
    ....
  8. ncbi Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma
    Ludmila Boudova
    Department of Pathology, Josef Schneider Str 2, D 97080 Wurzburg, Germany
    Blood 102:3753-8. 2003
    ..This morphologic pattern suggests a biologic continuum between NLPHL and T/HRBCL...
  9. ncbi Peripheral T-cell lymphoma with progression to a clonally related, Epstein Barr virus+, cytotoxic aggressive T-cell lymphoma: evidence for secondary EBV infection of an established malignant T-cell clone
    Rupert Langer
    Institute of Pathology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Am J Surg Pathol 34:1382-7. 2010
    ..This case shows that secondary EBV infection of an established malignant T-cell clone can occur and may contribute to aggressive transformation of PTCL...
  10. ncbi CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies
    Eva Geissinger
    Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany
    Leuk Lymphoma 50:1010-6. 2009
    ..Our approach helps to precisely define CD52 expression in the tumor cell population of PTCL and might therefore be valuable when evaluating the response to alemtuzumab therapy in prospective clinical trials...
  11. ncbi Evaluation of FoxP3 expression in peripheral T-cell lymphoma
    Irina Bonzheim
    Institute of Pathology, University of Wurzburg, Wurzburg, Germany
    Am J Clin Pathol 130:613-9. 2008
    ..Among ALCL cases, 4 of 6 ALK+ cases displayed weak and inhomogeneous FoxP3 expression in the tumor cells. FoxP3+ PTCL-NOS presumably derived from bona fide Treg cells occurs but seems rare in the Western population...
  12. ncbi Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations
    Andreas Zettl
    Department of Pathology, University of Wurzburg, Wurzburg, Germany
    Am J Pathol 164:1837-48. 2004
    ..The genetics of PTCL NOS and ALK-negative ALCL differ from other T-NHLs characterized genetically so far, among them enteropathy-type T-cell lymphoma, T-cell prolymphocytic leukemia, and adult T-cell lymphoma/leukemia...
  13. ncbi Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomas
    Irina Bonzheim
    Institute of Pathology, University of Wurzburg, Josef Schneider Strasse 2, 97080, Wurzburg, Germany
    J Hematop 1:11-21. 2008
    ..Therefore, SNPs in these genes are not associated with the apoptotic defect and autoimmune phenomena in AILT...
  14. ncbi 'Normal counterparts' of nodal peripheral T-cell lymphoma
    Thomas Rudiger
    Institute of Pathology, University of Wurzburg, Wurzburg, Germany
    Hematol Oncol 24:175-80. 2006
    ..A comparison between the lymphomas and their normal counterparts may contribute to the understanding of the underlying transformation mechanisms...
  15. ncbi Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations
    Eva Geissinger
    Institute of Pathology, University of Wuerzburg, Josef Schneider Strasse 2, Wuerzburg, Germany
    Haematologica 95:1697-704. 2010
    ..While all these entities are characterized by proliferation of highly atypical, anaplastic CD30(+) T cells, the expression of T-cell specific antigens in the tumor cells is not consistently detectable...
  16. ncbi IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution
    Zhengrong Mao
    Institute of Pathology, University of Wurzburg, Germany
    Am J Surg Pathol 31:1605-14. 2007
    ..HRS or HRS-like cells in all 3 unrelated cases showed evidence of Epstein-Barr virus infection. Of interest, 5/6 cases of B-CLL with HL, and 5/6 cases of B-CLL with HRS cells showed mutated IgVH genes...
  17. ncbi Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies
    Eva Geissinger
    Institute of Pathology, University of Wuerzburg, Josef Schneider Strasse 2, D 97080 Wuerzburg, Germany
    J Mol Diagn 7:455-64. 2005
    ..The combination of TCRVbeta polymerase chain reaction and immunohistochemistry may facilitate more reliable detection and characterization of tumor cells in PTCL...
  18. ncbi The role of high-dose therapy in peripheral T-cell lymphomas
    Peter Reimer
    Medizinische Poliklinik, University of Wuerzburg, Germany
    Clin Lymphoma Myeloma 6:373-9. 2006
    ..Overall, because data on high-dose therapy for PTCL are limited, larger and randomized studies are necessary to definitely confirm the preliminary results...
  19. ncbi Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study
    Peter Reimer
    Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany
    J Clin Oncol 27:106-13. 2009
    ..Therefore, we initiated the first prospective multicenter study on upfront autoSCT in PTCL and recently reported good feasibility and efficacy of this approach. Here, we present the final analysis of the study...
  20. ncbi Noninvasive imaging of angiogenesis inhibition following nitric oxide synthase blockade in the ischemic rat heart in vivo
    Christiane Waller
    Medizinische Universitatsklinik, Wurzburg, Germany
    Microcirculation 12:339-47. 2005
    ..Nitric oxide synthase inhibition has anti-angiogenic properties. Magnetic resonance (MR) imaging was used to image the functional significance of these microvascular changes in a rat model of chronic ischemic myocardium in vivo...
  21. ncbi Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study
    Peter Reimer
    Medizinische Poliklinik, University of Wuerzburg, Klinikstr 6 8, Wuerzburg, Germany
    Hematol J 5:304-11. 2004
    ..Our data suggest a substantial impact on outcome, however, longer follow-up is necessary to confirm survival benefit...
  22. ncbi Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence
    Martin Spahn
    Department of Urology and Paediatric Urology, University of Wurzburg, Wurzburg, Germany
    Int J Cancer 127:394-403. 2010
    ..Our results showed that progressive miR-221 downregulation hallmarks metastasis and presents a novel prognostic marker in high risk PCa. This suggests that miR-221 has potential as a diagnostic marker and therapeutic target in PCa...
  23. ncbi Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas
    Philipp Strobel
    Institute of Pathology, University of Wuerzburg, Germany
    Blood 100:159-66. 2002
    ..The acquisition of the CD45RA(+) phenotype on CD4(+) T cells during terminal intratumorous thymopoiesis is associated with the presence of MG in most thymoma patients...
  24. ncbi Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3
    German Ott
    Pathologisches Institut and Poliklinik für Innere Medizin, University of Wurzburg, Germany
    Blood 99:3806-12. 2002
    ....